← back to search

Simon Lord

University of Oxford · GB
Area of research
Radiology, Nuclear Medicine and Imaging · Oncology
Research interest
Research interests include HER2/EGFR in Cancer Research, Glioma Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, and Cancer, Hypoxia, and Metabolism.
h-index
28
citations
4,047
works
200
NIH funding
primary concept
Medicine
email

Recent publications

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications 2025cited by 1position: middledoi
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications 2023cited by 55position: middledoi
379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
Annals of Oncology 2023cited by 44position: middledoi
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications 2023cited by 0position: middledoi
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
npj Breast Cancer 2022cited by 38position: middledoi
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
The Lancet Oncology 2019cited by 559position: middledoi
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Proceedings of the National Academy of Sciences 2019cited by 127position: middledoi
Imaging tumour hypoxia with positron emission tomography
British Journal of Cancer 2014cited by 325position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Richard D. Baird · Cancer Research UK4 papers (2023–2025)Carlo Palmieri · University of Liverpool3 papers (2023–2025)Ashwani Bahl · Loughborough University3 papers (2023–2025)Janine Mansi · Guy's and St Thomas' NHS Foundation Trust3 papers (2023–2025) · 3 papers (2023–2025)Sacha J. Howell · University of Manchester3 papers (2023–2025)Jason M. Melear · The US Oncology Network3 papers (2023–2025)Linnea Chap · University of California, Los Angeles3 papers (2023–2025)Stuart McIntosh · Opsona Therapeutics (Ireland)3 papers (2023–2025)Laura Kenny · Imperial College Healthcare NHS Trust3 papers (2023–2025)Rinath Jeselsohn · Harvard University3 papers (2023–2025)Simak Ali · Hammersmith Hospital3 papers (2023–2025)Glen Clack · University of Sheffield3 papers (2023–2025) · 3 papers (2023–2025)Sagar Sardesai · Comprehensive Cardiovascular3 papers (2023–2025)R. Charles Coombes · Imperial College Healthcare NHS Trust3 papers (2023–2025)Zahi Mitri · BC Cancer Agency3 papers (2023–2025)Joyce O’Shaughnessy · Baylor University Medical Center3 papers (2023–2025)Matthew Krebs · Christie's3 papers (2023–2025)Pavani Chalasani · University of Arizona3 papers (2023–2025)